drugset

drugset / Trial / NCT00913965

To Demonstrate the Relative Bioavailability of Atenolol Tablets

NCT00913965 ↗

Phase 1 Completed 24 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Atenolol tablets.

Timeline

Start: 1989-07
Primary completion: 1989-08
Completion: 1989-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atenolol	Other / unclassified	100 mg	—

Indications